【出版时间及名称】：2009年12月美国儿童多动症专题研究报告
        【作者】：德意志银行
        【文件格式】：pdf
        【页数】：60
        【目录或简介】：
Table of Contents
Executive Summary........................................................................... 3
Outlook ....................................................................................................................................3
Valuation ..................................................................................................................................4
Risks ........................................................................................................................................4
Introduction to ADHD ....................................................................... 5
What is ADHD?.........................................................................................................................5
What are the criteria for ADHD diagnoses?..............................................................................7
Key ADHD statistics - United States and Worldwide................................................................8
Diagnosis rates of ADHD are increasing across the world .....................................................11
Very significant economic cost burden of ADHD in the United States ...................................11
Treatment of ADHD......................................................................... 12
Therapeutic options for treating ADHD...................................................................................12
Currently available ADHD therapies ........................................................................................18
Growth Prospects for ADHD Pharmaceuticals.............................. 22
It won’t be just a market for US pediatrics anymore...............................................................22
Recently launched and near-term potential products..............................................................24
Earlier stage product candidates.............................................................................................25
Generics and ADHD Outlook .......................................................... 29
Extended release stimulant generics have arrived ..................................................................29
Will the long-standing Citizen Petitions be rescinded? ...........................................................29
The impact of generic Adderall XR on Vyvanse’s growth prospects ......................................31
Survey Overview.....................................................................................................................32
Detailed results: payor survey.................................................................................................33
Detailed results: prescriber survey..........................................................................................35
Therapeutic substitution likely will not be as significant as in selected other chronic care
markets ..................................................................................................................................39
ADHD Market Forecasts.................................................................. 43
Base case scenario .................................................................................................................43
A plausible second scenario: Citizen Petitions are upheld by the FDA ...................................45
Appendix A: Detailed US Market Models..................................... 47
Appendix B: Detailed Survey Results ........................................... 50